Oct. 25 at 3:23 PM
$SLS the following thread is context for historical price gaps after PH3 top line release: What caused the sharp increase in share price for ABVX in July of this year?
The sharp increase in Abivax SA (NASDAQ: ABVX) share price in July 2025 was primarily triggered by the company’s announcement of positive top-line results from two Phase 3 clinical trials of its lead drug candidate, obefazimod, for the treatment of moderate to severe ulcerative colitis (UC). The data, released after market close on July 22, 2025, showed that obefazimod met its primary endpoint of clinical remission in both trials, marking a significant milestone for the oral therapy as a potential first-in-class treatment.
This news led to a dramatic single-day surge of over 580% in ABVX shares on July 23, 2025, with the stock opening in premarket trading up more than 400% before closing sharply higher. The rally was fueled by analyst upgrades and enthusiasm from biotech investors, who viewed the results as de-risking
